Time course response after single injection of botulinum toxin to treat spasticity after stroke: Systematic review with pharmacodynamic model-based meta-analysis
- PMID: 34634514
- DOI: 10.1016/j.rehab.2021.101579
Time course response after single injection of botulinum toxin to treat spasticity after stroke: Systematic review with pharmacodynamic model-based meta-analysis
Abstract
Background: The time-course response after a single injection of botulinum toxin (BoNT) for post-stroke spasticity is debated. We addressed this issue by conducting a systematic review and a pharmacodynamic model-based meta-analysis.
Methods: We searched Medline, PeDro and Google Scholar databases up to March 2020, selecting randomized controlled trials of post-stroke and traumatic brain injury patients with arm or leg muscle hypertonia, comparing BoNT to placebo, or different BoNT preparations. The main outcome was change in Modified Ashworth Scale (MAS) score. A non-linear mixed effect model was used to estimate maximal toxin and placebo effects (Emax and EPlacebo), the effect disappearance half-life (T1/2off) of BoNT and the doses achieving 50 and 80% of Emax (D50 and D80). The equivalence ratios between different BoNT preparations were calculated from D50 values. Adverse events were recorded.
Results: Altogether, 2,236 unique records were screened by 2 independent reviewers: 35 eligible trials including 3011 patients (95% post-stroke) were identified. For all BoNT preparations, the BoNT Emax of -1.11 (95% credible interval -1.31; -0.29) was reached at 5 weeks; the maximal placebo effect was -0.30 (-0.37; -0.22). Both D50 and D80 differed significantly by muscle volume. At D50, the equivalence ratio was significantly higher for abobotulinumtoxinA (3.35) than onabotulinumtoxinA and lower for letibotulinumtoxinA (0.41). T1/2off was longer for abobotulinumtoxinA than for onabotulinumtoxinA and the other preparations (13.1 weeks [95% credible interval 7.7; 19.3] vs 8.6 weeks [7.1; 10.1]). Adverse events were minor, with a weak, but significant, dose-response relation for muscle weakness.
Conclusions: This first pharmacodynamic model-based meta-analysis of individuals with stroke revealed that for all BoNT-A preparations, BoNT-A injections to treat spasticity have maximal effect at 5 weeks. The T1/2off was longer for abobotulinumtoxinA than other preparations. Differences between certain BoNT unit scales were also confirmed.
Keywords: Botulinum toxin; Dose response; Meta-analysis; Model-based; Muscle spasticity; Muscle tone; Stroke; Time course.
Copyright © 2021 Elsevier Masson SAS. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest Pascal Giraux and Etienne Ojardias received meeting sponsorship from Allergan, Ipsen, and Merz and compensation for consulting from Merz. Etienne Ojardias received through his institution a research support grant from Merz. Pascal Giraux is a co-founder of the Dessintey company. The other authors declare no conflict of interest.
Similar articles
-
Efficacy and safety of botulinum toxin type A for upper limb spasticity after stroke or traumatic brain injury: a systematic review with meta-analysis and trial sequential analysis.Eur J Phys Rehabil Med. 2017 Apr;53(2):256-267. doi: 10.23736/S1973-9087.16.04329-X. Epub 2016 Nov 11. Eur J Phys Rehabil Med. 2017. PMID: 27834471
-
Botulinum toxin type B for cervical dystonia.Cochrane Database Syst Rev. 2005 Jan 25;(1):CD004315. doi: 10.1002/14651858.CD004315.pub2. Cochrane Database Syst Rev. 2005. Update in: Cochrane Database Syst Rev. 2016 May 13;(5):CD004315. doi: 10.1002/14651858.CD004315.pub3. PMID: 15674941 Updated.
-
Botulinum toxin type A in the treatment of lower limb spasticity in cerebral palsy.Cochrane Database Syst Rev. 2000;(2):CD001408. doi: 10.1002/14651858.CD001408. Cochrane Database Syst Rev. 2000. PMID: 10796784
-
Botulinum toxins for the prevention of migraine in adults.Cochrane Database Syst Rev. 2018 Jun 25;6(6):CD011616. doi: 10.1002/14651858.CD011616.pub2. Cochrane Database Syst Rev. 2018. PMID: 29939406 Free PMC article.
-
Botulinum toxin in the treatment of rare head and neck pain syndromes: a systematic review of the literature.J Neurol. 2004 Feb;251 Suppl 1:I19-30. doi: 10.1007/s00415-004-1106-8. J Neurol. 2004. PMID: 14991339
Cited by
-
Trends in Botulinum Toxin Use among Patients with Multiple Sclerosis: A Population-Based Study.Toxins (Basel). 2023 Apr 12;15(4):280. doi: 10.3390/toxins15040280. Toxins (Basel). 2023. PMID: 37104218 Free PMC article.
-
Use of Botulinum Toxin in Upper-Limb Tremor: Systematic Review and Perspectives.Toxins (Basel). 2024 Sep 13;16(9):392. doi: 10.3390/toxins16090392. Toxins (Basel). 2024. PMID: 39330850 Free PMC article.
-
AbobotulinumtoxinA Doses in Upper and Lower Limb Spasticity: A Systematic Literature Review.Toxins (Basel). 2022 Oct 26;14(11):734. doi: 10.3390/toxins14110734. Toxins (Basel). 2022. PMID: 36355984 Free PMC article.
-
Long-Term Enhancement of Botulinum Toxin Injections for Post-Stroke Spasticity by Use of Stretching Exercises-A Randomized Controlled Trial.Toxins (Basel). 2024 Jun 11;16(6):267. doi: 10.3390/toxins16060267. Toxins (Basel). 2024. PMID: 38922161 Free PMC article. Clinical Trial.
-
A review about muscle focal vibration contribution on spasticity recovery.Front Neurol. 2025 Jun 4;16:1579118. doi: 10.3389/fneur.2025.1579118. eCollection 2025. Front Neurol. 2025. PMID: 40534747 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical